Press Release
G2GBio has the best experts in the field of innovative improved injectable drug development.
-
"G2GBio Announces Once-Monthly Semaglutide (GB-7001) Development .."G2GBio Announces Once-Monthly Semaglutide (GB-7001) Development Results at American Diabetes A..
2023.06.29 -
G2GBIO Signs Master Service Agreement with Global Pharmaceutical Compa..“G2GBIO Signs Master Service Agreement with Global Pharmaceutical Company for Microsphere Sustaine..
2023.04.26 -
G2GBio: "Positive Signal for Development of Monthly Donepezil (GB..G2GBio: "Positive Signal for Development of Monthly Donepezil (GB-5001) Formulation" ..
2023.04.17 -
G2GBIO, "Remarkable outcomes in non-clinical study for their Sema..G2GBIO, "Remarkable outcomes in non-clinical study for their Semaglutide microspheres"(Mon..
2023.04.11 -
G2GBio signs a Collaboration Agreement with a global pharmaceutical co..G2GBio signs a Collaboration Agreement with a global pharmaceutical company for long-acting diabetes..
2023.02.02 -
G2GBio has been selected as an "international collaborative techn..G2GBio has been selected as an "international collaborative technology development operator&quo..
2022.10.07 -
Korea Pharma, G2GBIO, Humedix ink deal for donepezil injection-based A..Korea Pharma said Wednesday that it signed a joint development contract with G2GBIO and Humedix to d..
2022.10.05 -
G2Gbio, “Initiates Phase 1 Clinical Trial in Canada” for GB-5001, ..G2Gbio, “Initiates Phase 1 Clinical Trial in Canada” for GB-5001, a monthly sustained release Al..
2022.08.30